Active Filter(s):
Details:
Proceeds from the financing will enable Intrance to initiate pivotal U.S. clinical trials for the company’s lead product, Lecigon® (in the Nordic countries and European markets) for enteral infusion (light weight infusion pump) in advanced Parkinson’s disease patients.
Lead Product(s): Carbidopa,Etilevodopa,Entacapone
Therapeutic Area: Neurology Product Name: Lecigon
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Erik Selin
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 04, 2022